Correction: Effectiveness of digital self-care device for at risk drinking problems: focus on individuals at risk for alcohol-related issues
Correction: Bridging reward and resilience: the endocannabinoid system as a unifying mechanism in exercise-induced protection against major depressive disorder
Cultural adaptation and feasibility of action over inertia in Japan: a multi-site pilot intervention study
Social anxiety but not callous-unemotional traits predicts shame coping in conduct disorder
Spatial CRISPR screens map total RNA in tissue
Nature Biotechnology, Published online: 11 June 2026; doi:10.1038/s41587-026-03126-z
A method for spatial CRISPR perturbation screening reveals how genetic changes alter coding and non-coding RNA in a native tissue context, including the tumor microenvironment.
Large-scale, spatially resolved panoramic CRISPR screening in native tissue environments using Perturb-DBiT
Nature Biotechnology, Published online: 11 June 2026; doi:10.1038/s41587-026-03127-y
In vivo CRISPR genetic perturbations are spatially mapped at scale.
Clinical Profile and Genomic Characterization of the 2026 Bundibugyo Virus Index Case in Uganda
Nature Medicine, Published online: 11 June 2026; doi:10.1038/s41591-026-04510-7
Clinical Profile and Genomic Characterization of the 2026 Bundibugyo Virus Index Case in Uganda
STAT+: Enliven Therapeutics’ leukemia drug shows promise in new study
A targeted drug from Enliven Therapeutics induced molecular responses in nearly half of patients with advanced leukemia, including higher response rates in patients treated at an earlier stage of their disease.
The updated early-stage study results reported Thursday for the Enliven drug, ELVN-001, compare favorably to a current blockbuster medicine sold by Novartis and an upstart experimental drug recently bought by Merck.
At 24 weeks, an 80 mg, once-daily dose of ELVN-001 achieved a major molecular response in 48% of patients with chronic myeloid leukemia, or CML, a slow-growing cancer that starts in myeloid cells.
STAT+: ‘Synthetic lethality’ could trigger another round of biotech M&A
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
Never before have I covered so much positive news about pancreatic cancer in such a short period of time. What happens next? Could Revolution Medicines buy Tango Therapeutics? Or, perhaps Bristol Myers Squibb goes all out and acquires Revolution Medicines?
To be clear, neither of these deals has been announced, or even rumored. I’m just playing the biotech M&A speculation game. But a strong case for something to happen can be made in the wake of Monday’s exciting report from Tango. In an early-stage clinical trial, patients with advanced pancreatic cancer benefited more from a combination of two targeted drugs — a PRMT5 inhibitor from Tango and Revolution’s pan-RAS inhibitor — than they might from each drug on its own.

